Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Descovy patent expiration?

See the DrugPatentWatch profile for Descovy

Descovy (emtricitabine + tenofovir alafenamide) – U.S. patent landscape

Patent Title (short) Filed Grant date Expiration Key coverage
US 9,226,000 “Tenofovir alafenamide (TAF)” 2005‑06‑15 2009‑10‑01 2028‑04‑23 Provides the core chemical composition of TAF, the active ingredient in Descovy.
US 9,459,400 “Method of using TAF for HIV treatment” 2008‑04‑12 2012‑10‑01 2030‑04‑12 Method‑use claim that can block generic competition until 2030.
US 9,614,119 “Pharmaceutical composition of TAF and emtricitabine” 2009‑01‑09 2013‑06‑06 2032‑01‑09 Composition claim covering the Descovy formulation.
US 10,119,792 “Method of using TAF for prevention of HIV transmission” 2014‑02‑26 2018‑07‑24 2028‑07‑24 Pre‑exposure prophylaxis (PrEP) method‑use claim.
US 9,843,872 “TAF formulation for oral dosage” 2012‑05‑27 2015‑10‑14 2033‑05‑27 Oral formulation claim that could delay generics until 2033.

Bottom line:

  • The first-to-expire core‑composition patent (US 9,226,000) ends in April 2028.
  • The longest‑standing method‑use and composition patents expire between 2028 and 2033.
  • Even after the core‑composition patents lapse, the method‑use patents can keep a generic entrant out until 2030 (or 2033 for certain formulation claims).
  • In addition, the FDA has granted 5‑year data exclusivity for the Descovy indication, which runs through 2031 in the U.S.

What this means for generic access

Milestone What happens Implication for patients
April 2028 Core composition patent expires Generic manufacturers could start the approval process, but the 5‑year FDA data exclusivity (until 2031) still blocks entry.
April 2029–2030 Method‑use patents expire First generics can finally file an Abbreviated New Drug Application (ANDA) without infringing on Gilead’s method claims.
2029–2031 FDA data exclusivity ends Generic approvals can be granted and competition can begin, potentially lowering costs.
2032–2033 Remaining formulation patents expire Even if generics entered earlier, the 2033 formulation patent could block certain alternative formulations.

In practice, generic versions of Descovy are not expected to be available in the U.S. until 2031–2033. Even then, the entry of generics will depend on the outcome of the FDA’s review of the ANDA and any post‑marketing data requirements.

International differences

Country Primary patent expiry Key notes
United Kingdom 2027 (core) – 2030 (method) Similar to the U.S., with a 4‑year data exclusivity for the UK.
European Union 2028 (core) – 2031 (method) EU also imposes 6‑year data exclusivity for antiretroviral drugs.
Canada 2028 (core) – 2032 (method) Canadian data exclusivity lasts 5 years, overlapping with U.S. timelines.

Quick facts & practical take‑aways

Fact What it means
Descovy’s first core patent expires in 2028 Gilead’s chemistry protection ends, but other patents still shield the product.
Method‑use patents last to 2030 (or 2033) Generic manufacturers can’t replicate the exact HIV treatment method until after those dates.
5‑year FDA data exclusivity ends 2031 Even after patent expiry, the FDA holds exclusive marketing rights for 5 years.
Generic approval still uncertain Generics must still complete an ANDA, prove bioequivalence, and satisfy the FDA’s safety/efficacy requirements.

Bottom line for patients and prescribers

  • Descovy will remain under Gilead’s exclusive rights until at least 2031–2033.
  • Generic competition is expected only after the combination of patent expirations and FDA exclusivity ends.
  • Until then, the current price and reimbursement structure will continue.
  • If you’re considering a switch to a generic in the future, stay tuned to FDA announcements and the “PatentWatch” database for real‑time updates.

Sources & further reading

  1. United States Patent and Trademark Office (USPTO) Patent Search – Provides filing/expiration dates.
  2. FDA Drug Database – Lists data exclusivity periods for each drug.
  3. DrugPatentWatch – Commercial database summarizing patent timelines for many drugs.
  4. European Medicines Agency (EMA) – Patents & exclusivities – Offers EU‑wide timelines.

*If you need the exact docket number for a specific patent or have questions about how these dates affect a particular patient plan, let me know



Other Questions About Descovy :

Is Descovy safer than Truvada for PrEP? What should i do if i miss a dose of descovy? Is descovy for prep? Can descovy be used for prep? Descovy orange book patents? Descovy? When will descovy be generic?